INTRODUCTION
ab T cells use their ab T cell antigen receptor (abTCR) to recognize an almost infinite number of peptide antigens presented by major histocompatibility complex molecules (pMHC) on antigen-presenting cells (APCs). In contrast, gd T cells have a rather limited germline-encoded receptor repertoire. Their gdTCRs in part recognize stress-induced self-antigens, lipids, or pyrophosphates that are secreted by some microbes or are overproduced in tumor cells (Bonneville et al., 2010; Chien and Konigshofer, 2007; Vantourout and Hayday, 2013) . gdTCRs can also deliver ligand-independent signals for gd T cell development in the thymus (Jensen et al., 2008) .
In mice, 1% of the gd T cells recognize the nonclassical MHC class I molecule T22, which is expressed on activated cells, such as lipopolysaccharide (LPS)-stimulated B cells (Crowley et al., 2000; Matis et al., 1987) . One example is the G8 gdTCR that uses its CDR3d loop to bind with high affinity to T22 (Adams et al., 2005; Crowley et al., 2000; Weintraub et al., 1994) .
In human blood, the main subset of gd T cells is Vg9Vd2 that accounts for 2%-10% of all T cells. The Vg9Vd2 TCR recognizes self and foreign nonpeptidic phosphorylated small organic compounds, collectively termed phosphoantigens (Bukowski et al., 1995 (Bukowski et al., , 1998 Constant et al., 1994; Espinosa et al., 2001; Tanaka et al., 1995) . Vg9Vd2 T cells are also stimulated by tumor cells, such as the Daudi B cell lymphoma , that likely express high levels of phosphoantigens (Gober et al., 2003) . Antigen recognition and tumor cell killing by Vg9Vd2 T cells can be enhanced with aminobisphosphonates, such as zoledronate (Roelofs et al., 2009) , which increase accumulation of endogenous phosphoantigen.
TCRs consist of a clonotypic TCRab or TCRgd heterodimer, two CD3 dimers (CD3dε, CD3gε), and a zz dimer. TCRab and TCRgd chains contain variable (V) immunoglobulin domains that bind to the antigen, and constant (C) domains that associate with CD3. CD3 and z contain tyrosines in their cytoplasmic tails that are phosphorylated upon antigen binding to TCRab or TCRgd. In this report, ''TCRab'' or ''TCRgd'' denote the TCRab or TCRgd heterodimers, and ''abTCR'' or ''gdTCR'' the complete TCRs including the CD3 and z chains. Although similar in domain structure, the architecture of gdTCRs differs from that of abTCRs (see the Discussion).
Stimulation of the abTCR and the gdTCR initiates intracellular signaling cascades, such as Ca 2+ influx, PI3K/AKT, Ras/Erk, and NFkB pathways that are extensively studied. However, how antigen binding to TCRab or TCRgd is communicated to the cytosolic tails of CD3 and z is less well understood (Kuhns and Davis, 2012) . It has been suggested that the abTCR exists in two conformations. In the closed conformation, adopted by the unstimulated abTCR, the cytosolic tails of CD3 and z might be shielded from phosphorylation (Minguet and Schamel, 2008) . In the open conformation, induced by productive antigen or antibody binding, CD3 and z phosphorylation might be promoted by an unknown mechanism.
The experimental assay to measure this CD3 conformational change (CD3 CC) makes use of the increased accessibility of a proline-rich sequence (PRS) in the CD3ε cytoplasmic tail. In the closed conformation, the PRS cannot bind to the first SH3 domain of the adaptor protein Nck. In contrast, in the open conformation the PRS is accessible and thus binds to this SH3 domain (Borroto et al., 2013 (Borroto et al., , 2014 de la Cruz et al., 2011; Gil et al., 2002 Gil et al., , 2005 Martínez-Martín et al., 2009; . In fact, PRS exposure is correlated with an overall rearrangement in the structure of the CD3 and z cytoplasmic tails (Risueñ o et al., 2008) .
The CD3 CC, as measured by PRS exposure, precedes CD3 phosphorylation (Gil et al., 2002) and is required for ab T cell activation , in that engineered ligands that could not induce the CD3 CC did not result in abTCR phosphorylation and downstream signaling. Likewise, point mutations in the extracellular part of CD3ε that do not allow the outside-in transmission of the CD3 CC, such as CD3εK76T or CD3εC80G, inhibit abTCR signaling in vitro and in vivo (Martínez-Martín et al., 2009) . Thus, without the CD3 CC, an abTCR cannot be activated.
CD3ε also contains a cytosolic basic-rich sequence that has been proposed to interact with the acidic lipids of the inner membrane leaflet, shielding the cytoplasmic CD3ε tyrosines from phosphorylation in the unstimulated abTCR (Deford-Watts et al., 2009; Xu et al., 2008) . Signaling by the abTCR leads to Ca 2+ -influx neutralizing the negative lipid head groups and thus, freeing the CD3ε cytosolic domain from the membrane and promoting sustained signaling after the initial abTCR trigger (Shi et al., 2013) . Whether Ca 2+ ions can influence the exposure of the PRS is currently unknown.
To date, studies exploring the induction of the CD3 CC in gdTCRs are lacking. Here, we tested if the CD3 CC can be induced in the mouse and human gdTCR and whether it regulates gd T cell activation.
RESULTS

Murine gdTCRs Undergo a Conformational Change at CD3ε upon Antibody Stimulation
To assess whether the gdTCR undergoes the CD3 CC upon stimulation, we used the murine gd T cell line F30L31 expressing a Vg1.1 TCR, and as a control the mouse ab T cell line 2B4. We carried out an SH3 pull-down (PD) assay using the first SH3 domain of Nck ( Figure 1A ). Anti-z western blotting showed that resting, unstimulated TCRs did not bind to the SH3-coupled beads ( Figure 1B , lanes 1 and 4), whereas stimulation with the anti-CD3 monoclonal antibody (mAb) 145-2C11 (2C11) at 37 C induced binding of the gdTCR and the abTCR to SH3 beads (lanes 2 and 5). Stimulation with the phosphatase inhibitor pervanadate (PV) did not trigger binding of the TCRs to SH3 (lanes 3 and 6). As a further control, we incubated the lysates with protein A-and G-coupled beads to immune-precipitate the TCRs via the bound anti-CD3 mAb (lower panels). In addition, anti-TCRgd antibody stimulation also induced gdTCR binding to SH3 ( Figure S1A ). A hallmark of the CD3 CC is its independence from any metabolic process (Gil et al., 2002 ; Minguet et al., The murine gd T cell hybridoma F30L31 and ab T cell hybridoma 2B4 were left untreated (À) and stimulated for 5 min at 37 C or 0 C with 5 mg/ml anti-CD3 mAb 2C11 or for 5 min with pervanadate (PV). After lysis, one aliquot of lysates was incubated with SH3 beads and another with protein Aand protein G beads. Lysates and bead-purified proteins were analyzed by anti-z WB (n > 3 2007); thus, it even took place at 0 C ( Figure 1B , lanes 8 and 10). This indicates that the induced binding of the gdTCR to SH3 reflects structural changes in CD3ε (the CD3 CC), as previously described for the abTCR.
In primary ex vivo gd T cells from TCRb À/À Vg1.1tg mice, both anti-CD3 and anti-Vg1.1, but not anti-TCRb mAbs, induced binding of the gdTCR to the SH3 beads ( Figure 1C ). Thus, mouse gdTCRs undergo conformational changes at CD3 upon stimulation with gdTCR-and CD3-specific antibodies.
Next, we tested whether the TCR-mediated Ca 2+ influx, which was proposed to expose the cytosolic tail of CD3 in case of the abTCR (Shi et al., 2013) , was involved in the induction of the CD3 CC, as measured by the SH3-PD assay ( Figure 1D ). To this end, we left F30L31 gd and 2B4 ab T cells unstimulated (À) or stimulated them with anti-CD3 (2C11) in the absence of Ca 2+ ions in the medium, lysis, and washing buffers (all containing EGTA). Alternatively, the stimulation was performed in the presence of Ca 2+ in these buffers and an optional treatment of the cells with ionomycin to allow Ca 2+ to flux into the cytosol. The presence or absence of Ca 2+ did not influence the amount of TCRs bound to the SH3-coupled beads, neither basally nor upon antibody stimulation ( Figure 1D ). Thus, Ca
2+
-induced structural changes in the TCR are not related to the CD3 CC, and the CD3 CC most likely is upstream of TCR-induced Ca 2+ influx.
Antigen Binding to Mouse G8 gdTCRs Does Not Trigger the CD3 CC Next, we tested whether natural antigens induce the structural rearrangement of CD3ε in the gdTCR. For this purpose, we made use of a murine hybridoma cell line expressing the G8 gdTCR (Bluestone et al., 1988) specific for the MHC I-like molecule T22 (Schild et al., 1994) . Upon stimulation of the G8 gd hybridoma with biotinylated T22 monomers or tetramers for 5 min at 37 C, the CD3 CC was not induced ( Figure 2A , lanes 2 and 3). Surprisingly, tetramer binding to the G8 gdTCR significantly reduced the CD3 CC, as compared to the basal level (Figures 2A, right panel, and S1B) . As a control, we used anti-CD3 stimulation to trigger the CD3 CC. In contrast to the gdTCR, MHC class I H2-K d -pepABA (pMHC) tetramers induced the CD3 CC in the mouse T1.4 ab hybridoma ( Figure 2B ), as previously described . The G8 gd hybridoma cells bound similar amounts of antigen tetramers as the T1.4 ab hybridoma cells ( Figure S1C ); thus, low levels of T22 tetramer binding were not responsible for the lack of CD3 CC detection in the gdTCR.
Next we used LPS-activated splenic B cells expressing endogenous T22 as antigen-presenting cells (APCs) (Spaner et al., 1995) . Again, stimulation of the G8 gd hybridoma tended to reduce the CD3 CC ( Figure S1D ). Thus, using the best-characterized antigen for a specific gdTCR, our results showed that a natural antigen did not induce the CD3 CC and even evoked a slight reduction in the amount of conformationally changed TCRs upon stimulation.
The Capacity to Undergo the CD3 CC Maps to the TCRab Constant Regions To test whether the gd cellular environment inhibited CD3 CC induction, we expressed the G8 gdTCR in the murine ab hybridoma 58a À b À defective for TCRa and TCRb expression, yielding 58.VgdCgd cells ( Figure 2C , left panel, and S2). Stimulation with T22 tetramers did not induce the CD3 CC ( Figure 2D , lanes 1-3), indicating that the T22-G8 gdTCR system intrinsically lacks the ability to undergo the CD3 CC.
Hence, our findings raised the question whether, in contrast to conventional pMHC tetramers, the T22 antigen is in principle incapable of inducing the CD3 CC, or whether it is intrinsic to the G8 gdTCR that productive antigen engagement does not result in the CD3 CC. To test these opposing possibilities, we generated chimeric gd-ab TCRs and expressed them in 58a Figures 2C and S2 ). 58.VabCab cells express the T1 abTCR, 58.VabCgd cells a chimeric TCR with the V regions from T1 TCRab and the C regions from G8 TCRgd, and 58.CDR3dVCab cells express the 172 abTCR with the T22-binding CDR3d region of the G8 TCRd chains as reported .
Strikingly, pMHC-tetramer stimulation of the chimeric VabCgd TCR did not induce the CD3 CC, but rather reduced the basal level ( Figure 2D , lanes 7-9). In contrast, in the CDR3dVCab the T22 tetramers induced the CD3 CC ( Figure 2D , lanes 10-12) that was statistically significant compared to unstimulated cells ( Figure 2E ). Thus, neither the different binding geometry nor the different affinity of the T22-gdTCR compared to the pMHC-abTCR interaction determined CD3 CC induction. Rather the G8 gdTCR is intrinsically different from the abTCR, because the constant regions of the TCRgd chains do not transmit the conformational change to CD3 upon antigen binding.
Ligand-induced TCR activation leads to intracellular signaling, causing TCR internalization. Our wild-type (WT) and chimeric TCRs were internalized upon stimulation with their corresponding T22 or pMHC tetramers, indicating that induction of the CD3 CC was not required for gdTCR activation ( Figure 2F ).
Triggering of the CD3 Conformational Change in the Human Vg9Vd2 TCR Next, we tested whether the CD3 CC can be induced in a human Vg9Vd2 gd T cell clone (Fisch et al., 1990b; . Stimulation with the anti-CD3 mAb UCHT1 triggered the CD3 CC ( Figure 3A , lanes 2 and 8). However, the more commonly used anti-CD3 mAb OKT3 showed markedly reduced potency in the induction of the CD3 CC at 37 C and was completely inactive at 0 C (lanes 3 and 9). However, similar amounts of TCR were bound by UCHT1 and OKT3, because protein Aand G-coupled beads precipitated similar amounts of antibody-bound TCRs (z chain detection, lower panels). As expected, anti-TCRgd but not pervanadate (PV) stimulation induced the CD3 CC (lanes 6 and 4). The same result was obtained with a different Vg9Vd2 T cell clone (data not shown). Similarly, when using human freshly isolated, purified gd T cells, OKT3 was a less potent inducer of the CD3 CC as compared to UCHT1 or anti-TCRgd ( Figure 3B ).
In contrast, UCHT1 and OKT3 equally induced the CD3 CC in human Jurkat ab T cells ( Figure 3C, lanes 2 and 3) . The lack of structural changes at CD3 in the gdTCR upon OKT3 stimulation could be due to the gdTCR itself or differing cellular environments in gd compared to ab T cells. To distinguish between these possibilities, we used a TCRb-deficient Jurkat cell line expressing the human Vg9Vd2 TCR (Jk.Vg9Vd2) ). Again, UCHT1 was much more potent than OKT3 in triggering the CD3 CC (Figures 3C, lanes 5 and 6, S3A, and S3B). In conclusion, UCHT1 was a much more potent trigger for the CD3 CC in the human Vg9Vd2 TCR than OKT3, and differential induction of the CD3 CC in the human gdTCR compared to the human abTCR is due to intrinsic properties of these TCRs.
The human Vg9Vd2 TCR is naturally stimulated by phosphoantigens (Bukowski et al., 1995; Constant et al., 1994) . We stimulated the Vg9Vd2 T cell clone with the two most commonly used synthetic phosphoantigens bromohydrin pyrophosphate (BrHPP) or isopentenyl pyrophosphate (IPP) (Espinosa et al., 2001 ) and could not detect the CD3 CC above background ( Figure 3D , lanes 2 and 3). As a positive control, UCHT1 triggered the CD3 CC (lane 4). Furthermore, stimulation with Daudi cells or zoledronate (ZOL)-pulsed Daudi cells with increased levels of endogenous phosphoantigens (Roelofs et al., 2009 ) did not induce the CD3 CC (Figures 3E, lanes 2 and 3, and S3C).
Next, we quantified tumor necrosis factor (TNF)-a production using the same concentration of the stimuli as for the CD3 CC assay ( Figure 3F ). UCHT1 induced TNF-a production to an extent similar that obtained via stimulation by Daudi or Daudi+ZOL, and 4-fold less compared to IPP. Hence, induction of the CD3 CC did not correlate with TNF-a production, indicating that CD3 CC induction is not required for TNF-a production by gd T cells. As a control, stimulation with Daudi cells neither induced the CD3 CC in the Vg9Vd2 clone nor activated an ab T cell clone ( Figures 3E and 3F ).
In conclusion, using phosphoantigens as well as antigenexpressing Daudi cells, we did not detect the CD3 CC in human Vg9Vd2 TCRs. This is in strong contrast to the abTCR where stimulation with pMHC tetramers and APCs induce this conformational change (de la Cruz et al., 2011; Gil et al., 2005 Gil et al., , 2008 Risueñ o et al., 2005 Risueñ o et al., , 2006 .
CD3 CC Induction at the gdTCR Correlates with Activation of TCR-Proximal Signaling Events
To investigate the influence of the CD3 CC on gdTCR activation, we compared the effects of UCHT1 and OKT3 on human gd T cells using different functional readouts. To ensure that equal numbers of gdTCRs were stimulated, we used both mAbs at 5 mg/ml-a concentration at which similar amounts of gdTCRs were bound to UCHT1 and OKT3 ( Figure 3A ). Although UCHT1 stimulation evoked a strong Ca 2+ influx, OKT3 led to a much weaker response in the Vg9Vd2 T cell clone ( Figure 4A ) and in freshly isolated, purified human gd T cells ( Figure 4B ). In ab Jurkat cells in which both UCHT1 and OKT3 induced the CD3 CC ( Figure 3C ), both antibodies triggered a strong Ca 2+ influx ( Figure S4A ).
Using a multiplexed bead assay, we assessed the phosphorylation kinetics of signaling proteins downstream of the TCR, such as Akt, Erk, and IkBa. In the Vg9Vd2 T cell clone, UCHT1 triggered a transient and strong phosphorylation of all three proteins ( Figure 4C ). In sharp contrast, OKT3 stimulation led to a slow and gradual increase in phosphorylation. A similar result was obtained with human purified gd T cells ( Figure S4B ). In addition, Vg9Vd2 TCR downmodulation from the cell surface was slightly enhanced by UCHT1 compared to OKT3 ( Figure S4C ). We conclude that triggering of the CD3 CC in the gdTCR led to enhanced proximal signaling events, as compared to stimulation in the absence of the CD3 CC. Figure 5A , lane 5). The gd-specific pattern of CD3 glycosylation is dependent on the expression of the TCRgd chains and not the cellular background . In an ab cellular background (Jk.Vg9Vd2 cells) OKT3 was also unable to induce the CD3 CC in the gdTCR ( Figure 3C ). However, deglycosylation allowed the CD3 CC to take place ( Figure S4D ). Deglycosylation also increased the CD3 CC induced by UCHT1 ( Figure 5A ), indicating that this effect is not specific for OKT3. Next, we tested whether supplementing OKT3 stimulation with the CD3 CC by deglycosylating the gd T cells influences TCR-induced signaling. Although OKT3 stimulation alone did not result in a measurable Ca 2+ influx ( Figure 5B ), enhanced Ca 2+ influx was detected when the Vg9Vd2 T cell clone was deglycosylated prior to OKT3 stimulation ( Figure 5B ). Thus, the specific glycosylation of the gdTCR controls inducibility of the CD3 CC and its associated signal transduction. C with 5 mg/ml of the anti-CD3 mAbs UCHT1 and OKT3, pervanadate (PV) or antiTCRgd (clone 5A6E9). Cells were also stimulated for 30 min at 0 C. After lysis, the SH3-PD was performed (n > 3).
(B) Freshly isolated, purified human gd T cells (gdPBMCs) were stimulated for 5 min at 37 C with 5 mg/ml UCHT1, OKT3, and anti-TCRgd mAbs, and the SH3-PD was performed (n = 1).
(C) Jurkat and Jk.Vg9Vd2 cells were stimulated for 30 min at 0 C with 5 mg/ml UCHT1 and OKT3, and the SH3-PD was performed (n > 3).
(D) BrHPP (500 nM) or IPP (30 mM) was added to the Vg9Vd2 clone. Cells were gently centrifuged and left at 37 C for 60 min or stimulated for 5 min with UCHT1 as above. Cells were mildly lysed using 0.3% Brij58. The SH3-PD was performed (n > 3).
(E) The human Vg9Vd2 and a human ab T cell clone were left unstimulated and stimulated for 30 min with Daudi cells, zoledronate (ZOL)-pulsed Daudi cells or as a control, with 5 mg/ml UCHT1. The SH3-PD was performed (n > 3). The statistics were performed as in Figure 2A ; n.s., not significant. (F) The Vg9Vd2 (left) and ab (right) T cell clones were stimulated with Daudi, ZOL-pulsed Daudi cells, 30 mM IPP, or 5 mg/ml UCHT1 for 18 hr. TNF-a concentration was measured by ELISA (n > 3). The mean ± SD is shown.
Multimerization of OKT3 Facilitates the CD3 CC, Thereby Enhancing Ca 2+ Influx
For the abTCR, antigen-TCR interactions of high valency favor the induction of the CD3 CC (Minguet and Schamel, 2008) . In order to enable OKT3 to simultaneously bind to more than two gdTCRs, we costimulated with an anti-k antibody that binds to the k light chain of OKT3. Indeed, under these conditions the CD3 CC in the gdTCR was induced ( Figure 5C , lane 6). Interestingly, anti-k had little or no effect on UCHT1 induction of the CD3 CC (lanes 2 and 5). Accordingly, anti-k treatment enabled OKT3-triggered Ca 2+ influx in gd T cells ( Figure 5D , upper panel). As a control, anti-k did not significantly enhance Ca 2+ influx stimulated by UCHT1 (lower panel). Likewise, OKT3 multimerization using an anti-mouse immunoglobulin (Ig) G antibody led to CD3 CC induction and Ca 2+ influx ( Figures S4D and S4E ). These experiments suggest that the differences in triggering signaling downstream of the gdTCR by soluble UCHT1 or OKT3 are due to their differential capacity to induce the CD3 CC.
gdTCRs Containing Mutant CD3 CC-Defective CD3ε Chains Had Reduced Capability to Induce Ca 2+ Influx
Next, we made use of two CD3ε mutants, K76T and C80G, that weakly and a strongly inhibit induction of the CD3 CC ( Figure 5E ) (Martínez-Martín et al., 2009 ). WT and mutant murine CD3ε chains were expressed in the mouse gd F30L31 cells, yielding F.εWT, F.εK76T, and F.εC80G cells. By using IRES-GFP constructs, those cells expressing the exogenous CD3ε can be identified. The GFP + F.εWT, F.εK76T, and F.εC80G cells expressed similar gdTCR levels on their surface ( Figure S5A ). When they were stimulated with anti-CD3 mAb, a strong correlation between the capacity to induce the CD3 CC and the extent of Ca 2+ flux was observed (GFP + gated cells, Figure 5F ), again
showing that Ca 2+ influx is promoted by the CD3 CC.
Induction of the CD3 CC Suppresses CD69 Upregulation and Cytokine Secretion by gd T Cells Next, we tested whether the CD3 CC is required for the activation of gdTCR-induced distal events such as upregulation of the activation markers CD69 and CD25, cytokine secretion or proliferation. To this end, we stimulated the murine F.εWT, F.εK76T, and F.εC80G cells with anti-CD3; we found that CD69 and CD25 were induced in both WT and CD3 CC mutant CD3ε-expressing gd T cells ( Figure 6A ; data not shown). In fact, significantly more cells upregulated CD69 when the CD3 CC was suppressed ( Figure 6A ). To corroborate this finding in human cells, our Vg9Vd2 T cell clone was stimulated using soluble OKT3 and UCHT1 mAbs. Again, OKT3 led to a slightly better induction of CD69 and CD25 on the cell surface ( Figure 6B ). In human freshly isolated, purified gd T cells, CD69 and CD25 were upregulated to a similar extent by both soluble UCHT1 and OKT3 ( Figure 6C ).
At the same time, we measured cytokines secreted into the supernatant using a multiplexed bead assay. Surprisingly, OKT3 induced a much greater release of interferon (IFN)-g and TNF-a as compared to UCHT1 at all concentrations tested (Figures 6D and S5B) . In contrast, when we stimulated the ab T cell clone, which can undergo the CD3 CC induced by either UCHT1 or OKT3 stimulation, equal amounts of IFN-g and TNF-a were secreted ( Figure S5C ). Next, we multimerized UCHT1 and OKT3 by adhesion to a plastic dish, promoting conditions in which OKT3 induces the CD3 CC. As expected, secretion of IFN-g and TNF-a was similar in cells stimulated with plate-bound OKT3 or UCHT1 ( Figure 6E ).
Similar to cytokine secretion, soluble OKT3 induced stronger proliferation of short-term cultured human gd T cells than UCHT1 ( Figures 6F and S5D) .
Induction of the CD3 CC Promotes gd T Cell-Mediated Tumor Lysis
Because the CD3 CC differentially influences gd T cell activation, we asked whether Vg9Vd2 T cell effector functions, such (C) The human Vg9Vd2 T cell clone was stimulated with 5 mg/ml UCHT1 and OKT3 for 1, 3, 5, and 15 min. Phospho-Akt (solid line, y axis on left), phosphoErk (dashed line, y axis on right), and phospho-IkBa were measured by a multiplexed-bead assay performed on cell lysates. All panels were performed n > 3. The mean ± SD is shown.
as tumor cell lysis, can be modulated by altering the CD3 CC. Stimulating gd T cell cultures from different healthy donors with 0.5 or 5 mg/ml UCHT1 (which induces the CD3 CC) dramatically enhanced target cell lysis of the pancreatic tumor cell line Panc89 such that all tumor cells were lysed by 24 hr ( Figures 7A, 7B , and S6). In contrast, OKT3 (which hardly triggers the CD3 CC) did not enhance tumor lysis. High concentrations of anti-CD3 mAbs induced cell death in activated gd T cells (Janssen et al., 1991; Kabelitz et al., 1994) . Therefore, we examined lower mAb concentrations as well as different effector/target cell ratios. UCHT1, but not OKT3, augmented tumor cell killing by the gd T cells also at 0.05 mg/ml ( Figures  7B and S6A ) and at different effector/target ratios using gd T cell cultures from different donors ( Figure S6A ). The effect of UCHT1 was dependent on gd T cells, because the growth of Panc89 cells alone was neither affected by UCHT1 nor by OKT3 ( Figure 7C ). In most cases OKT3 had a blocking effect on tumor cell lysis ( Figures 7A, 7B , and S6A), as demonstrated previously (Fisch et al., 1990a) . The differential activity of the two antibodies was neither due to differences in the induction of gd T cell apoptosis ( Figure S6B ) nor to antibody-dependent cellular cytotoxicity, because most gd T cells in our cultures (>97%) and Panc89 cells were negative for CD16 (data not shown). In conclusion, induction of the CD3 CC by UCHT1 drastically enhanced the tumor-killing capacity of human gd T cells. T cell clone 2.5 mg/ml anti-k was added simultaneously with 5 mg/ml UCHT1 or OKT3 as indicated.
(E) Extent of CD3CC induction in the CD3εK76T and CD3εC80G mutants.
(F) F.εWT, F.εK76T, and F.εC80G cells were stimulated with 10 mg/ml anti-mouse CD3 (2C11), and Ca 2+ influx was measured while gating on the GFP + cells. All panels were performed n = 3, except (C) and (D), which were performed n = 2.
Last, we transduced our gd T cell cultures with lentiviral vectors encoding murine CD3εWT and CD3εK76T. Murine CD3εC80G was not expressed well on human T cells (not shown). In both cultures, approximately 5% of the cells expressed the murine CD3ε with a similar MFI (64 for CD3εWT and 67 for CD3εK76T, not shown). Stimulation with the anti-mouse CD3 mAb 2C11, which is a strong inducer of the CD3 CC (Figures 1  and 2 ), enhanced tumor cell killing by cells expressing CD3εWT more than those expressing CD3εK76T ( Figure S6C) . A similar result was obtained in a second experiment ( Figure S6D ). These experiments corroborate our finding that the CD3 CC promotes gd T cell cytotoxicity.
DISCUSSION
Here we show that a hallmark of the mechanism behind abTCR triggering does not hold true for the three gdTCRs tested. The CD3 CC is required for abTCR activation (Martínez-Martín et al., 2009; and thus is induced by all agonistic pMHCs tested (de la Cruz et al., 2011; Gil et al., 2005 Gil et al., , 2008 Risueñ o et al., 2005 Risueñ o et al., , 2006 Risueñ o et al., , 2008 . To investigate whether the abTCR and gdTCR share the same activation principle, we used the best-described ligands available. First, using the murine G8 gdTCR we show that, despite T22 tetramer binding and triggering of signaling, the CD3 CC was not induced. In fact, T22 tetramer and APC stimulation even had the reverse effect in stabilizing the closed CD3 conformation, indicating that the gdTCR structure was sensitive to T22 binding. Second, the human Vg9Vd2 TCR was activated by phosphoantigens, but the CD3 CC was not observed, although we used conditions that allow its detection in the abTCR (de la Cruz et al., 2011; Gil et al., 2008) . Therefore, the gdTCRs tested do not undergo the CD3 CC upon engagement by their ligands, which is in sharp contrast to the abTCR ( Figure S7A) .
In neither ab nor gdTCRs was exposure of the PRS influenced by the presence or absence of Ca 2+ ions. This indicates that the CD3 CC is different from the proposed Ca 2+ -dependent detachment of the CD3ε cytoplasmic tail from the membrane (Shi et al., 2013) , and most likely it occurs upstream of TCR-induced Ca 2+ signaling. Likewise, the absence of the CD3ε basic-rich sequence, required for membrane binding of the CD3ε tail, did not influence the CD3 CC (de la Cruz et al., 2011) .
What might be the difference between gdTCRs and abTCRs that precludes the CD3 CC upon antigen stimulation of the gdTCR? First, a low antigen-gdTCR affinity can be excluded, because the T22-G8 TCRgd interaction is high affinity K D z100 nM (Crowley et al., 2000) , compared to z10 mM for typical pMHC-TCRab interactions (Davis et al., 1998) . Second, using chimeric TCRs, we observed that induction of the CD3 CC did not depend on pMHC versus T22 binding, but on the C regions of the TCRab heterodimer. Thus, it is unlikely that the differential geometry of the T22-gdTCR interaction compared to the pMHC-abTCR interaction (Adams et al., 2005; Rudolph et al., 2006) is the cause for the absence of this structural change in the gdTCR.
The capacity to undergo the CD3 CC (or not) mapped to the C regions of TCRgd/TCRab. In fact, the constant Ig domains of TCRgd use different amino acids to associate with CD3 than do those of the TCRab (Allison et al., 2001) , which is in line with previous data suggesting that TCRab are oriented differently toward CD3 compared to TCRgd (Van Neerven et al., 1990) . For example, the constant Ig domain of TCRb contains an FG loop that is thought to directly associate with CD3 (Touma et al., 2006) and that is not present in TCRgd. The structural difference might be subtle, because in both TCR types the CD3 dimers might be located on the same side (Kuhns et al., 2010) . Thus, our data suggest that the arrangement of the complete TCRgd-CD3-z complex might sterically hinder antigen-induced conversion into the open CD3 conformation. In contrast to antigens, anti-TCR mAbs can force the gdTCR to adopt the CD3 open conformation. Thus, it is possible that some gdTCRs could undergo the CD3 CC upon binding to their ligand.
Despite the fact that the anti-human CD3 mAbs UCHT1 and OKT3 recognize overlapping epitopes at CD3ε (Arnett et al., 2004 ; Kjer-Nielsen et al., 2004), UCHT1 induced the CD3 CC in Figure 6 . Induction of the CD3 CC Reduces Anti-CD3-Induced Cytokine Secretion in Vg9Vd2 T Cells (A) F.CD3εWT, F.CD3εK76T, and F.CD3εC80G cells were stimulated for 7 hr with 3 mg/ml plate-bound 2C11 followed by staining the cells with anti-CD69 and gating on the GFP + cells for analysis by flow cytometry (n = 3). The mean ± SD is shown. One-way ANOVA and post hoc Tukey HSD tests were used: ***p < 0.001.
(B) The Vg9Vd2 T cell clone was stimulated in triplicates for 4 (CD69) or 20 (CD25) hr with 5 mg/ml soluble UCHT1 or OKT3 and stained with anti-CD69 or anti-CD25 for flow cytometry (n > 3). (C) Human freshly isolated, purified gd T cells (gdPBMCs) were stimulated for 20 hr and analyzed as in (B) (n = 1).
(D) The cellular supernatants from (B, 4 hr) were used to measure IFN-g and TNF-a by a multiplexed bead assay (IFN-g n = 2, TNF-a n = 3).
(E) The Vg9Vd2 T cell clone was stimulated with 5 mg/ml plate-bound UCHT1 or OKT3 in triplicates and secreted IFN-g and TNF-a were quantified as above (n = 2). (F) Expanded primary blood gd T cells were labeled with 1 mM Cell Trace Violet and left unstimulated or stimulated with 5 mg/ml soluble UCHT1 or OKT3 as indicated. After 4 days, proliferation was determined by flow cytometry (left panel) (n = 3). In (B)-(E), mean ± SD of triplicates is shown. Significances between UCHT1-and OKT3-stimulated cells were determined by the Student's t test; ns, not significant; *p < 0.05; **p < 0.01; ***p < 0.001.
the gdTCR, whereas OKT3 did not. This was intrinsic to the gdTCR. In contrast, both mAbs triggered the CD3 CC in the abTCR. OKT3 therefore resembles the T22 ligand in the murine system. Thus, mAbs can be useful tools for studying the TCR but do not always mimic antigen engagement. The gdTCR is more extensively glycosylated on CD3 compared to the abTCR (Alarcon et al., 1987; Krangel et al., 1987; Van Neerven et al., 1990) . Indeed, we show that desialylation of gd T cells enabled OKT3 to induce the CD3 CC in the Vg9Vd2 TCR. This gd-specific CD3 glycosylation was dependent on the expression of TCRgd and not the cellular background , which correlates with the inability of OKT3 to induce the CD3 CC in Jk.Vg9Vd2 T cells. CD3 deglycosylation (or deglycosylation of other cell surface proteins) might also enhance gdTCR clustering, promoting the CD3 CC. In ab T cells, the CD3 CC was required for abTCR triggering (Martínez-Martín et al., 2009; Minguet and Schamel, 2008) . We observed activation of human Vg9Vd2 T cells and murine G8 gd T cells by antigen in the absence of detectable induction of the CD3 CC ( Figure S7A ). Furthermore, mutating CD3ε such that its capacity to undergo the CD3 CC was reduced (Martí-nez-Martín et al., 2009) did not impair upregulation of the activation marker CD69 in murine Vg1.1 T cells. Thus, in contrast to abTCRs, the three different gdTCRs tested did not require the CD3 CC for several T cell activation readouts. Perhaps the absence of CD3 CC at the gdTCR is compensated by higher kinase levels (Laird and Hayes, 2010) , expression of different kinases (Latour et al., 1997; Saint-Ruf et al., 2000) , or a higher capacity to cluster (Jensen et al., 2008) . Indeed, gd T cells have an intrinsically stronger signaling capacity (Haks et al., 2005; Hayes et al., 2005) and may not need the CD3 CC to amplify activation signals as ab T cells do.
Artificial induction of the CD3 CC in the human Vg9Vd2 TCR by stimulation with UCHT1 had a strong impact on gd T cell activation. Compared to OKT3, UCHT1 stimulation enhanced proximal gdTCR-induced signaling events, such as Ca 2+ influx and activation of the PI3K/AKT, Ras/Erk and IkB/NFkB pathways ( Figure S7B ). Complementing OKT3 with the CD3 CC by T cell desialylation, anti-k light chain or anti-igG treatment resulted in augmented proximal signaling, suggesting that the CD3 CC was the cause for this increased activation. Indeed, Ca 2+ influx was reduced in the CD3 CC-defective mutant murine gdTCRs. This is in line with ab T cells, in which the CD3 CC is required for proximal signaling (Martínez-Martín et al., 2009; Minguet and Schamel, 2008) . Furthermore, the lack of CD3 CC during gdTCR triggering explains the slow kinetics (in comparison to those of ab T cells) and weak intensities of proximal signaling when human Vg9Vd2 T cells were stimulated with phosphoantigens and OKT3 (Beetz et al., 2008; Correia et al., 2009; Lafont et al., 2001 ), but not with UCHT1 (Lafont et al., 2001) . In contrast to proximal signaling events, production of the effector cytokine IFN-g and TNF-a by the Vg9Vd2 cells was reduced when the CD3 CC was present. It seems likely that strong proximal signaling supported by the CD3 CC (UCHT1) activates negative feedback loops, which decreases signaling at later time points. Indeed, UCHT1 enhanced TCR downregulation compared to OKT3. Thus, the lack of negative feedback loops upon OKT3 stimulation might explain the heightened ability of OKT3 to trigger cytokine production. Indeed, gd T cells are strong cytokine producers (Bonneville et al., 2010; Chien and Konigshofer, 2007; Vantourout and Hayday, 2013) .
Immunotherapy using gd T cells is garnering ever-increasing interest and has been tested in several early phase clinical trials for different cancers (Bennouna et al., 2008; Dieli et al., 2007; Kobayashi et al., 2007; Wilhelm et al., 2003; Xu et al., 2008) . gd T cells may be expanded in vivo (Dieli et al., 2007) or ex vivo and adoptively transferred (Bennouna et al., 2008; Kobayashi et al., 2011; Nicol et al., 2011) . In fact, allogeneic transplantation is now being considered a doable option, because gd T cells do not incite graft-versus-host disease, while offering considerable graft-versus-malignancy effects (Daniele et al., 2012) . One limiting factor is that patient-derived gd T cells, especially from those who have received chemotherapy or prior zoledronate treatment, often undergo suboptimal and highly variable ex vivo expansion (Kobayashi et al., 2011; Nicol et al., 2011) . We show here that OKT3 stimulation, which does not induce the CD3 CC at the gdTCR, promotes strong proliferation. Thus, it may be ideally suited for the expansion of gd T cells and was used for this purpose before (Dokouhaki et al., 2010) .
Besides cellular expansion strong gd T cell activation might be also required for therapeutic efficacy (Pennington et al., 2005) . We found that induction of the CD3 CC enhanced the PI3K/Akt and Ras/Erk pathways that are necessary for the antitumor activity of Vg9Vd2 T cells (Correia et al., 2009 ). Thus, UCHT1, which induces the CD3 CC, strongly enhanced gd T cell-mediated tumor cell killing, resulting in death of all tumor cells. In sharp contrast, OKT3 slightly blocked the tumor killing activity of the Vg9Vd2 T cells in most experiments. This was neither due to enhanced gd T cell proliferation nor increased IFN-g or TNF-a production by UCHT1-stimulated cells, because OKT3 triggered greater proliferation as well as IFN-g and TNF-a production than UCHT1. UCHT1 and OKT3 also induced similar amounts of apoptosis in the gd T cells. The conclusion that the CD3 CC promotes gd T cell cytotoxicity could be confirmed by genetic means using the CD3 CC mutant CD3ε in the tumor-killing assay.
Thus, employing these two mAbs may constitute an ideal combination in the development of gd T cell immunotherapy for a variety of cancers. Phosphoantigen stimulation at culture initiation followed by OKT3 stimulation should ensure generation of sufficient gd T cell numbers for infusion (Dokouhaki et al., 2010; Lopez et al., 2000) and UCHT1 stimulation just prior to infusion would enhance cytotoxicity.
In summary, our study identifies fundamental differences in gdTCR versus abTCR triggering mechanisms, which have likely evolved in response to differences in the respective antigens recognized by these receptors. Our findings, suggesting the use of UCHT1 or other drugs inducing the CD3 CC in human gd T cells, may inform the design of novel clinical immunotherapy protocols.
EXPERIMENTAL PROCEDURES
Cells, Mice, Reagents, and Cloning This information is given in the Supplemental Information.
Cell Stimulation, Lysis, and Nck-PD Assay Cells were stimulated for 5 min or the indicated times at 37 C or for 30 min on ice with 5 mg/ml anti-TCR. Cells were lysed at a maximum of 30 3 10 6 cells/ml in 1 ml lysis buffer containing the indicated detergent (0.3% Brij96V or 0.3% Brij58) as described (Schamel et al., 2005) . Fifty microliters were kept as a lysate control. For the SH3-PD assay, 600 ml were incubated with 3-5 ml glutathione-Sepharose beads bound to the first SH3 domain of Nck for 3 hr at 4 C (Gil et al., 2002) . Beads were washed vigorously four times in lysis buffer containing 0.5% Brij96V. Three hundred microliters of the lysate was used to confirm antibody binding of the stimulating antibodies by immunoprecipitations using 3 ml protein G-and 3 ml protein A-coupled Sepharose (Amersham Pharmacia Biotech) as described (Schamel et al., 2005) . T1.4 ab hybridoma cells were incubated with photoreactive H2-K d -pepABA monomers or tetramers. Subsequently, cells were UV-irradiated to covalently crosslink the pMHC to the T1.4 abTCR. Upon lysis, the SH3-PD was performed as above.
For stimulation by APCs, we used splenic B cells from CD3ε knock out C57BL/6 mice (avoiding contamination by T cells) that were stimulated overnight with 5 mg/ml LPS, Daudi cells, or Daudi cells pulsed for 4 hr with 2 mM zoledronate 10 hr before use. T cells were mixed with the APCs at a 1:1 (gd T cell:Daudi cell) or 1:2 (G8 gd T cell hybridoma:splenic APC) ratio. After stimulation and lysis, the SH3-PD was performed as above. For the unstimulated cells, T cells and APCs were lysed separately, and the lysates were combined for the SH3-PD.
Activation Assays
For the measurement of phosphorylated Erk, Akt, and IkBa, cells were stimulated and lysed and a multiplexed bead assay was performed using BioPlex200 system as per the manufacturer's instruction (Bio-Rad). To induce TCR downmodulation or CD69 and CD25 upregulation cells were plated at 2 3 10 5 per 96-well plate well and soluble antibodies were added at a concentration of 5 mg/ml. Cells were incubated at 37 C as indicated. Supernatants were kept at À80 C, and the relative amount of IFN-g and TNF-a was measured within 2 weeks on the BioPlex200 system following the manufacturer's instruction (Bio-Rad). Alternatively, TNF-a was measured using an ELISA kit (BD Biosciences).
Ca 2+ Flux and Flow Cytometry
Cells were labeled in the dark with 5 mg/ml of Indo-1 and 0.5 mg/ml of pluronic F-127 (both Molecular Probes and Life Technologies) for 45 min in RPMI, 1% fetal calf serum. After 1 min of recording at 37 C, cells were stimulated with 5 mg/ml OKT3 or UCHT1 mAb with or without 2.5 mg/ml of the indicated crosslinking antibody. The change of the ratio of Indo-bound versus Indo-unbound was followed for 300 s with a LSRII fluorescence spectrometer (BD Biosciences). Data were analyzed with the FlowJo 6.1 software.
Tumor Cell Killing Assay Adherent pancreatic ductal adenocarcinoma Panc89 cells were added to wells of an E-plate of a Real Time Cell Analyzer (Roche) for 24 hr. The impedance of the tumor cells was measured over this time period. After 24 hr, when the tumor cells were in the linear growth phase, the indicated concentrations of anti-CD3 mAb or medium together with the short-term cultured gd T cell lines were added. The loss of impedance after addition of gd T cells was measured over additional 24 hr. As a control for maximal lysis, Triton X-100 was added to the Panc89 cells. (A) The murine γδ T-cell hybridoma F30L31 was stimulated for 5 min at 37°C with 5 µg/ml of the anti-TCRγδ mAb GL3. After lysis, one part of the lysates was incubated with SH3-beads and another part with protein A-and protein G-beads. Lysates and bead-purifed proteins were analyzed by anti-ζ WB.
SUPPLEMENTAL INFORMATION
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This experiment shows that the murine γδTCR can undergo the CD3 CC upon anti-TCR γδ mAb stimulation.
(B) G8 γδ T cells were stimulated with 1, 5, 10 and 20 µg/ml T22t or 5 µg/ml anti-TCRγδ mAb (GL3) for 5 min, and the SH3-PD assay was performed. This titration of the T22 tetramer suggested that tetramer binding to the G8 γδTCR significantly reduced the CD3 CC at different ligand concentrations, as compared to the basal level.
(C) G8 γδ hybridoma cells were incubated with 5 µg/ml T22 tetramers and T1.4 αβ hybridoma cells with 5 µg/ml H2-K d -pepABA tetramers. Both tetramers were prepared from the same stock of PE-labelled streptavidin, thus the PE fluorescence measured by flow cytometry can be compared. Unstained cells served as a negative control. This experiment shows that binding of the G8 γδ hybridoma cells to T22
tetramers is comparable to that of T1.4 αβ hybridoma cells binding to pMHC tetramers.
(D) The G8 γδ hybridoma was kept unstimulated or stimulated for 1 hr at 37°C with LPS-activated splenic B cells from a CD3ε-deficient mouse or with 2C11. The SH3-PD was performed as before. The significance between unstimulated and APC-stimulated cells was determined by the Student's t-test; ns:
non significant. This experiment shows that stimulation of the G8 γδTCR by its natural ligand T22 did not induce the CD3 CC. We detected a small reduction in the basal CD3 CC suggesting again that T22 had a small impact on the γδTCR conformation. (A) Jurkat (αβTCR-expressing) and Jk.Vγ9Vδ2 (γδTCR-expressing) cells were left untreated (-) or stimulated for 5 min at 37°C with 5 µg/ml of the anti-CD3 mAbs UCHT1 and OKT3 or pervanadate (PV).
After lysis the SH3-PD assay was performed (n=3).
(B) Jk.Vγ9Vδ2 cells were left untreated or stimulated for 5 min at 37°C with 5 µg/ml of anti-TCRγδ mAbs.
After lysis the SH3-PD was performed (n=2).
(C) Jk.Vγ9Vδ2 cells were stimulated in triplicate as in main figure 3E . The ratio of SH3-bound TCR to total TCR (ζ) was calculated using the Odyssey infrared imager. The mean ± standard deviation (SD) is
shown. Significance between unstimulated and cells stimulated with Daudi+ZOL was determined by the Student's t-test; n.s. = not significant.
These experiments demonstrate that UCHT1 and anti-TCRγδ mAbs, but neither OKT3 nor ZOL-pulsed Daudi cells, trigger the CD3 CC in a γδTCR independent of the cellular environment. The experiments shown in all panels were done at least three times (n=3). The experiments in (C) and (D) suggest that expression of murine CD3ε and stimulation with 2C11 can enhance the cytotoxicity of these human γδ T cells, and that a reduced capacity to undergo the CD3 CC reduces the anti-tumoral activity. Thus, the CD3 CC is required for efficient tumor killing. Cloning and expression of the chimeric TCRs. The CDR3δVCαβTCR has been published . Here we inserted before the start codon of CDR3δ172α or 172β with a fusion-PCR a XhoI restriction site and a mouse TCRδ leader peptide sequence. A stop codon was inserted at the original place followed by a XbaI restriction site. The resulting PCR products were cloned into pLXV-IRES-ZsGreen1 (Clontech Lab). TCRα -β -cells were transduced with virus containing CDR3δ172α or 172β plasmids and plated to obtain single
clones. Transduced cells were tested for TCR expression by anti-CD3 (2C11) flow cytometry.
The CMV promoter of the lentiviral vector pLVX-IRES-ZsGreen1 (Clontech Lab) was exchanged by the SFFV promoter from the pHRSIN CSGW plasmid. Furthermore, the VαβCγδ and VγδCαβ TCRs were generated by joining the T1 TCRα and G8 TCRδ sequences, as well as the T1 TCRβ and G8 TCRγ sequences at the V-C borders as defined by the respective exons (see also Figure S2A ). For each chimeric TCR, one sequence was cloned into pLVX-S IP and the other one into pLVX-S IH. All constructs were verified by sequencing.
58α
-β -cells were transduced with lentivirus supernatants encoding for both chains and cotransduced cells were selected with puromycin (PAA) and hygromycin B (Invitrogen).
Transduced cells were tested for TCR expression by anti-CD3 (2C11) flow cytometry.
Cloning and expression of the mutant CD3ε molecules. Murine CD3ε wild-type as well as the CD3εK76T mutant sequences were amplified from pHRSIN CSGW plasmids and cloned into pLVX-S IZ. The CD3εC80G mutant sequence was derived from the wt CD3ε sequence by site-directed mutagenesis. All constructs were verified by sequencing. F30L31 and human γδ T cells were transduced with lentivirus encoding for the wt or mutant CD3ε chains.
Proliferation assay. γδ T-cell cultures derived from healthy donor PBMC were generated as described (Siegers et al., 2012) . On day 9, γδ T cells were labeled with 1 µM Cell Trace Violet (CTV, Invitrogen, Burlington, Canada) and resuspended at 10 6 cells/ml in complete medium: RPMI 1640 with 10% fetal bovine serum, 1x MEM NEAA, 10 mM HEPES, 1 mM
